Data completeness
0/8 — Limited
Drug data last refreshed 2h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DIUTENSEN-R is an oral fixed-dose combination tablet containing methyclothiazide (a thiazide diuretic) and reserpine (an antihypertensive alkaloid). This combination product is designed to treat hypertension by reducing blood volume and peripheral vascular resistance through dual mechanisms. The product targets patients requiring combination antihypertensive therapy.
Pre-Launch
Early-stage product with no linked commercial roles; limited immediate career opportunity pending regulatory approval and market entry.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DIUTENSEN-R currently presents zero linked job openings and remains in pre-launch stage, limiting near-term career opportunities. Career interest should focus on launch preparation roles at Bausch Health and long-term positions as the product moves toward market entry and subsequent commercial execution.
Brand ManagerCommercial Strategy Lead
Worked on DIUTENSEN-R at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.